Assessment of Energy Metabolic Changes in Adipose Tissue-Derived Stem Cells.
Hajmousa G., Harmsen MC.
Laboratory Study, published in Methods Mol Biol (2017) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Methods Mol Biol (2017)
- Country
- United States
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 28229407
- DOI
- 10.1007/978-1-4939-6756-8_5
- Citations
- 2
Abstract (original English)
Adipose tissue-derived stem cells (ADSC) are promising candidates for therapeutic applications in cardiovascular regenerative medicine. By definition, the phenotype ADSCs, e.g., the ubiquitous secretion of growth factors, cytokines, and extracellular matrix components is not met in vivo, which renders ADSC a culture "artefact." The medium constituents therefore impact the efficacy of ADSC. Little attention has been paid to the energy source in medium, i.e., glucose, which feeds the cell's power plants: mitochondria. The role of mitochondria in stem cell biology goes beyond their function in ATP synthesis, because it includes cell signaling, reactive oxygen species (ROS) production, regulation of apoptosis, and aging. Appropriate application of ADSC for stem cells therapy of cardiovascular disease warrants knowledge of their mitochondrial phenotype and function. We discuss several methodologies for assessing ADSC mitochondrial function and structural changes under environmental cues, in particular, increased ROS caused by hyperglycemia.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.